PharmaJet’s needle-free system to power Scancell’s melanoma Phase 3 after strong DNA therapy data
PharmaJet’s needle-free device will deliver Scancell’s DNA immunotherapy in a Phase 3 melanoma trial. Find out what this means for the future of cancer vaccines.